Cost effectiveness of deferasirox compared to desferrioxamine in the treatment of iron overload in lower-risk, transfusion-dependent myelodysplastic syndrome patients

References

• Gattermann N. Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Int J Hematol 2008;88:24-29
   PubMed Web of Science ®Google Scholar
• Wells RA, Leber B, Buckstein R, et al. Iron overload in myelodysplastic syndromes: a Canadian consensus guideline. Leuk Res 2008;32:1338-1353
   PubMed Web of Science ®Google Scholar
• Srinivasan S, Schiffer CA. Current treatment options and strategies for myelodysplastic syndromes. Expert Opin Pharmacother 2008;9:1667-1678
   PubMed Web of Science ®Google Scholar
• Frytak JR, Henk HJ, De Castro CM, et al. Estimation of economic costs associated with transfusion dependence in adults with MDS. Curr Med Res Opin 2009;25:1941-1951
   PubMed Web of Science ®Google Scholar
• Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005;23:7594-7603
   PubMed Web of Science ®Google Scholar
• Bennett JM. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol 2008;83:858-861
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology™: Myelodysplastic Syndromes. 1-31 2008. www.nccn.org
   Google Scholar
• Rose C, Brechignac S, Vassilief D, et al. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myelodysplasies). Leuk Res 2010;34:864-870
   PubMed Web of Science ®Google Scholar
• Fox F, Kundgen A, Nachtkamp K, et al. Matched-pair analysis of 186 MDS patients receiving iron chelation therapy or transfusion therapy alone. Blood (ASH meeting abstracts) 114, 2009
   Google Scholar
• Raptis A, Duh MS, Wang ST, et al. Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices. Transfusion 2009
   Google Scholar
• Leitch HA, Wong DHC, Leger CS, et al. Improved leukaemia-free and overall survival in patients with myelodysplastic syndrome receiving iron chelation therapy: a subgroup analysis. Abstract 1469. 49th American Society of Haematology meeting, Atlanta Georgia USA, 8-11th December, 2007
   Google Scholar
• Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-2302
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006;107:3455-3462
   PubMed Web of Science ®Google Scholar
• Swedish Orphan International Ltd. Ferriprox Summary of Product Characteristics, 2008
   Google Scholar
• Novartis Pharmaceuticals. Opinions of three UK clinicians treating MDS patients. Data on file, 2009
   Google Scholar
• Karnon J, Tolley K, Oyee J, et al. Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom. Curr Med Res Opin 2008;24:1609-1621
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Porter J, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin: prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica 2009;95:557-566
   PubMed Web of Science ®Google Scholar
• Schmid M, Guerci-Bresier A, Porta MD, et al. Deferasirox (Exjade®) is effective and well tolerated in chelation-naive and previously chelated patients with transfusion-dependent myelodysplastic syndromes (MDS). Abstract 3806. 51st American Society of Haematology meeting, New Orleans, LA, USA, 6--9th December, 2009
   Google Scholar
• List A, Baer M, Steensma D, et al. Two-year analysis of efficacy and safety of deferasirox (Exjade®) treatment in myelodysplastic syndrome patients enrolled in the US03 study. Abstract 3829. 51st American Society of Haematology meeting, New Orleans, LA, USA, 6-9th December, 2009
   Google Scholar
• Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceuticals UK Ltd. Deferasirox summary of product characteristics. 2009. http://emc.medicines.org.uk/
   Google Scholar
• Novartis Pharmaceuticals UK Ltd. Desferrioxamine summary of product characteristics. http://emc.medicines.org.uk/
   Google Scholar
• Vichinsky E, Onyekwere O, Porter J, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 2007;136:501-508
   PubMed Web of Science ®Google Scholar
• Porter JB. Concepts and goals in the management of transfusional iron overload. Am J Hematol 2007;82:1136-1139
   PubMed Web of Science ®Google Scholar
• Glanville J, Eleftheriou P, Porter J. MRI evidence of cardiac iron accumulation in myelodysplasia and unusual anaemias. Blood (ASH annual meeting abstracts) 108, 2006
   Google Scholar
• Rose C. Iron chelation therapy improves survival in regularly transfused MDS Patients. A prospective analysis by the GFM. Slides presented at American Society of Haematology (ASH) meeting 2007 Data on file, 2007
   Google Scholar
• Rose C, Brechignac S, Vassilief D, et al. Positive impact of iron chelation therapy (CT) on survival in regularly transfused MDS patients. A prospective analysis by the GFM. Abstract 249, 49th American Society of Haematology meeting, Atlanta Georgia USA, 8-11th December, 2007
   Google Scholar
• Novartis Pharmaceuticals. Western General Hospital data on MDS. Personal correspondence data on file, 2008
   Google Scholar
• Sanz G, Nomdedeu B, Such E, et al. Independent impact of iron overload and transfusion dependency on survival and leukaemic evolution in patients with myelodysplastic syndrome. Blood (American Society of Haematology Annual Meeting Abstracts) 2008 112: Abstract 640, 2008
   Google Scholar
• Jaeger M, Aul C, Sohngen D, et al. Iron overload in polytransfused patients with MDS: Use of L1 for oral iron chelation. Drugs Today 1992;28(Suppl A):143-147
   Google Scholar
• Delea TE, Hagiwara M, Phatak PD. Retrospective study of the association between transfusion frequency and potential complications of iron overload in patients with myelodysplastic syndrome and other acquired hematopoietic disorders. Curr Med Res Opin 2009;25:139-147
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Bejaoui M, Agaoglu L, et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or desferroxamine for iron overload in patients with beta-thalassemia. Clin Ther 2007;29:909-917
   PubMed Web of Science ®Google Scholar
• Porter JB, Bowden D, Ganser A, et al. Satisfaction and adherence significantly improves in patients with β-thalassaemia and myelodysplastic syndromes treated with deferasirox (Exjade®). Abstract 1306. 50th American Society of Haematology meeting, San Francisco, California USA, 6-9th December, 2008
   Google Scholar
• Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making 1993;13:89-102
   PubMed Web of Science ®Google Scholar
• Wong JB, Koff RS, Tine F, et al. Cost effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995;122:664-675
   PubMed Web of Science ®Google Scholar
• Barr R, Furlong W, Henwood J, et al. Economic evaluation of allogeneic bone marrow transplantation: a rudimentary model to generate estimates for the timely formulation of clinical policy. J Clin Oncol 1996;14:1413-1420
   PubMed Web of Science ®Google Scholar
• British National Formulary 59. March 2010. Deferasirox. http://bnf.org/bnf/bnf/59/129929.htm?q=exjade&t=search&ss=text&p=1#_129929
   Google Scholar
• Sourced from Chemist and Druggist website 26/02/2010. http://www.chemistanddruggist.co.uk/
   Google Scholar
• Menzin J, Lang K, Earle CC, et al. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med 2002;162:1597-1603
   PubMed Web of Science ®Google Scholar
• Luengo-Fernandez R, Leal J, Gray A, et al. Cost of cardiovascular diseases in the United Kingdom. Heart 2006;92:1384-1389
   PubMed Web of Science ®Google Scholar
• Diabetes UK. Diabetes. Beware the silent assassin. A report from Diabetes UK, October 2008. http://www.diabetes.org.uk/Documents/Reports/Silent_assassin_press_report.pdf
   Google Scholar
• Shepherd J, Jones J, Hartwell D, et al. Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2007;11:1-205
   PubMed Web of Science ®Google Scholar
• Varney SJ, Guest JF. The annual cost of blood transfusions in the UK. Transfus Med 2003;13:205-218
   PubMed Web of Science ®Google Scholar
• National Institute of Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal. June 2008
   Google Scholar
• Desrosiers MP, Payne K, Proskorovsky I, et al. Estimated total annual costs of infused iron chelation therapy in the United Kingdom. Poster 0810. 11th Congress of the European Haematology Association, Amsterdam, The Netherlands, 15-18th June 2006
   Google Scholar
• Delea TE, Sofrygin O, Thomas SK, et al. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective. Pharmacoeconomics 2007;25:329-342
   PubMed Web of Science ®Google Scholar
• The Scottish Medicines Consortium (SMC). Guidance to Manufacturers for completion of New Product Assessment Form (NPAF) (Clinical and Economic Sections combined). 2010. Available from: URL: http://www.scottishmedicines.org.uk/
   Google Scholar
• Abetz L, Baladi JF, Jones P, et al. The impact of iron overload and its treatment on quality of life: results from a literature review. Health Qual Life Outcomes 2006;4:73
   PubMed Web of Science ®Google Scholar
• Taher A, Cappellini MD. Update on the use of deferasirox in the management of iron overload. Ther Clin Risk Manag 2009;5:857-868
   PubMedGoogle Scholar
• Porter JB, Bowden D, Ganser A, et al. Improved health-related quality of life in patients with haematological disorders receiving deferasirox (Exjade®). Blood (American Society of Haematology Annual Meeting Abstracts) 2008 112. Abstract 1307
   Google Scholar
• Osborne RH, De Abreu LR, Dalton A, et al. Quality of life related to oral versus subcutaneous iron chelation: a time trade-off study. Value Health 2007;10:451-456
   PubMed Web of Science ®Google Scholar
• Arboretti R, Tognoni G, Alberti D. Pharmacosurveillance and quality of care of thalassaemic patients. A large scale epidemiological survey. Eur J Clin Pharmacol 2001;56:915-922
   PubMed Web of Science ®Google Scholar